Raymond James’ Rahul Sarugaser bumped his Knight Therapeutics Inc. target to $7.50 from $7 with an “outperform” rating. The average is $6.56.
“GUD is situating itself as the go-to LATAM partner for U.S.- and EU-focused pharma companies looking to capture value from their best-in-class drugs in the region (one of the world’s fastest growing pharma markets), potentially driving material (and, importantly, non-binary) positive returns for shareholders,” he said. “We believe GUD’s trusted governance (oversight by Canadian regulators), its formidable on-the-ground infrastructure (more than 650 LATAM FTEs, 3 manufacturing plants, plus R&D and distribution centres), alongside the strong track record GUD is accruing in the region (winning marketing approvals with 11 disparate regulators, securing large contracts from national Ministries of Health) advantages GUD in licensing discussions with future and current pharma/biotech partners seeking to participate in LATAM markets.”